Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 21, Issue 3, Pages 201-223Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41573-021-00337-8
Keywords
-
Funding
- Alexander von Humboldt Foundation
- European Research Council (ERC) [695054]
- German Center for Diabetes Research (DZD e.V.)
- German Research Foundation [TRR152, TRR296]
- European Research Council (ERC) [695054] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Enormous progress has been made in managing diseases associated with excess body weight, but treatment of obesity itself remains challenging. By summarizing the history and advancements in anti-obesity medications, researchers are now pursuing next-generation AOMs that could safely and effectively achieve weight loss.
Enormous progress has been made in the last half-century in the management of diseases closely integrated with excess body weight, such as hypertension, adult-onset diabetes and elevated cholesterol. However, the treatment of obesity itself has proven largely resistant to therapy, with anti-obesity medications (AOMs) often delivering insufficient efficacy and dubious safety. Here, we provide an overview of the history of AOM development, focusing on lessons learned and ongoing obstacles. Recent advances, including increased understanding of the molecular gut-brain communication, are inspiring the pursuit of next-generation AOMs that appear capable of safely achieving sizeable and sustained body weight loss.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available